This trial is active, not recruiting.

Conditions aids-related kaposi sarcoma, hiv infection, recurrent kaposi sarcoma
Treatments bortezomib, laboratory biomarker analysis, questionnaire administration
Phase phase 1
Target proteasome
Sponsor National Cancer Institute (NCI)
Start date January 2010
End date September 2014
Trial size 24 participants
Trial identifier NCT01016730, AMC-063, CDR0000659554, NCI-2012-03170, U01CA121947


This pilot, phase I trial studies the side effects and best dose of bortezomib in treating patients with acquired immune deficiency syndrome (AIDS)-related Kaposi sarcoma that has come back or has not responded to treatment. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Patients receive bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
bortezomib [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid
Given IV
laboratory biomarker analysis
Correlative studies
questionnaire administration
Ancillary studies

Primary Outcomes

MTD based on the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
time frame: 56 days

Secondary Outcomes

Change in lytic gene expression
time frame: Baseline to 1 year
Changes in bortezomib in KSHV copy number in PBMC and plasma
time frame: Baseline to 1 year
Changes in levels of tumor survival, proliferation proteins, and NFKappaB gene target mRNA levels
time frame: Baseline to 1 year
Changes in viral antigen expression in biopsy specimens
time frame: Baseline to 1 year
Clinical KS response rates based on the Response Evaluation Criteria in Solid Tumors
time frame: Up to 1 year

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Adult patients with cutaneous AIDS-related biopsy-proven KS relapsed after or refractory to at least one other prior systemic therapy - Patients must have cutaneous KS lesion(s) amenable to biopsy (either one lesion >= 12 mm or 3 >= 4 mm) in addition to at least 5 lesions measurable for assessment; all of these lesions must not have been previously radiated - Must have been on stable anti-retroviral therapy for at least 12 weeks with a principal investigator (PI)-based or non-nucleoside reverse-transcriptase inhibitor (NNRTI)-based regimen of at least three drugs, with no intention to change the regimen for the duration of the study; patients who have a high likelihood of better HIV management with a new antiretroviral regimen should defer enrollment until the changes are in place and the new highly active antiretroviral therapy (HAART) regimen meets the 12 week criteria - Serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), positive western blot, or other Food and Drug Administration (FDA)-approved licensed HIV test, or a detectable blood level of HIV RNA - Women of child-bearing potential must have a negative pregnancy test within 72 hours before initiation of study drug dosing; post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential; male and female subjects of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug; (Note: a woman of childbearing potential is one who is biologically capable of becoming pregnant; this includes women who are using contraceptives or whose sexual partners are either sterile or using contraceptives) - Absolute neutrophil count (ANC) >= 1,000/mm^3; subjects may be receiving growth factor support to meet these criteria - Hemoglobin >= 8.0 gm/dL; subjects may be receiving growth factor support to meet these criteria - Platelets >= 100,000/mm^3 - Total bilirubin =< 1.5 mg/dL; if the elevated bilirubin is felt to be secondary to indinavir or atazanavir therapy, then subjects will be allowed on protocol without any limit on the total bilirubin if the direct bilirubin is normal - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal (ULN) - Serum creatinine =< institutional ULN or creatinine clearance >= 50 mL/min/1.73 m^2 for subjects with creatinine levels above institutional ULN - Pre-existing grade 3 or 4 peripheral neuropathy Exclusion Criteria: - KS that is improving in the 4 weeks prior to enrollment - Symptomatic visceral KS (oral and lymph node involvement is eligible) - Symptomatic pulmonary KS; asymptomatic pulmonary KS that is not limiting activities of daily living is allowable - Eastern Cooperative Oncology Group (ECOG) performance status greater than 2 - Expected survival < 3 months with standard KS treatments (i.e., radiation, paclitaxel) - Concurrent active opportunistic infection (OI) - Herpes zoster (shingles) outbreak within the last 6 months or inability to take herpes zoster prophylaxis - Patient is =< 5 years free of another primary malignancy except if the other primary malignancy is neither currently clinically significant nor requiring active intervention, or if the other primary malignancy is a localized squamous or basal cell skin cancer or cervical/anal carcinoma in situ - Acute treatment for an infection or other serious medical illness within 14 days prior to study entry - Patients may not have had anti-neoplastic treatment for Kaposi sarcoma (including chemotherapy, radiation therapy, biological therapy, or investigational therapy) within 4 weeks (6 weeks for nitrosourea or mitomycin-C) of study treatment - Prior treatment with bortezomib or other investigational proteasome inhibitors - Previous local therapy of any KS indicator lesion within 60 days, unless the lesion has clearly progressed with enlargement since the local therapy - Use of any investigational drug or treatment within 4 weeks prior to randomization - Physical or psychiatric conditions that in the estimation of the investigator place the patient at high risk of toxicity or non-compliance - Hypersensitivity to boron - Subjects with grade III/IV cardiac disease as defined by the New York Heart Association criteria. (e.g., congestive heart failure, myocardial infarction within 6 months of study) - Subject has an acute or known chronic liver disease (e.g., chronic active hepatitis, cirrhosis); subjects with known hepatitis B or C infection may be enrolled if they have either documentation of no or minimal fibrosis on liver biopsy or undetectable hepatitis virus on polymerase chain reaction (PCR) - Systemic corticosteroid treatment, other than replacement doses - Female subjects who are pregnant or breast-feeding

Additional Information

Official title Single-Arm, Dose-Finding Pilot Trial of Single-Agent Bortezomib in Patients With Relapsed/Refractory AIDS-Associated Kaposi Sarcoma With Correlative Assessments of KSHV and HIV
Principal investigator Erin Reid
Description PRIMARY OBJECTIVES: I. Estimate the maximum tolerated dose (MTD) of single agent bortezomib in subjects with AIDS-related Kaposi sarcoma (KS). SECONDARY OBJECTIVES: I. Evaluate the clinical response of KS tumors to bortezomib. II. Evaluate the impact of bortezomib on human immunodeficiency virus (HIV) plasma viral loads and peripheral blood mononuclear cells (PBMC) apolipoprotein B messenger ribonucleic acid (mRNA) editing enzyme, catalytic polypeptide-like 3G (APOBEC3G) levels. III. Determine the impact of bortezomib on Kaposi's sarcoma-associated herpesvirus (KSHV). IV. Assess bortezomib effects on KSHV copy number in PBMC and plasma and whether changes in viral copy number measured in PBMC and plasma are associated with clinical response of KS tumors. V. Monitor KSHV gene expression in KS biopsy specimens and PBMC pre- and post-bortezomib and assess whether changes in viral gene expression (i.e., to a lytic pattern) in tumor biopsy are associated with clinical response. VI. Assess whether changes in viral copy number in PBMC and plasma occur in concert with or independently of changes in viral antigen expression in tumor biopsy specimens. VII. Assess effects of bortezomib on proteins relevant to KS tumor survival and proliferation (i.e., P53, von Hippel-Lindau [VHL], p27, hypoxia-inducible factor 1 [HIF1]-alpha) as well as levels of nuclear factor-kappaB (NFkappaB) gene target mRNAs in tumor biopsies. OUTLINE: This is a dose-escalation study. Patients receive bortezomib intravenously (IV) on days 1, 8, and 15. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 4 weeks and then every 3 months for up to 1 year.
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).